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ABSTRACT
In total, 48 Mycobacterium tuberculosis clinical
isolates from 48 patients with drug-resistant pul-
monary tuberculosis (TB) in central Poland during
2004 were analysed by spoligotyping and IS6110-
Mtb1 ⁄Mtb2 PCR. Twelve (25%) isolates were
clustered by spoligotyping in combination with
IS6110-Mtb1 ⁄Mtb2PCR.Patients fromwhomthese
isolates were obtained were assumed to have
developed TB as a result of recent transmission.
Spoligotyping, used alone, overestimated the num-
ber of clustered isolates.However, combineduse of
spoligotyping and IS6110-Mtb1 ⁄Mtb2 PCR was an
efficient approach for revealing clonal relatedness
among M. tuberculosis isolates.
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This report describes the molecular characterisa-
tion of drug-resistant Mycobacterium tuberculosis
isolates recovered from tuberculosis (TB) patients
in central Poland during 2004. This was achieved
by using a combination of spoligotyping [1] and
IS6110-Mtb1 ⁄Mtb2 PCR [2]. The phenotypic char-
acteristics of the isolates were also determined.
The study included 48 M. tuberculosis isolates
from 48 unrelated adult TB patients (age range,
18–85 years; median age, 48 years; 38 men and
ten women) from central Poland. The population
examined represented 7% of all bacteriologically
confirmed cases of TB notified in this region
during 2004, and 20% of the total number of
drug-resistant pulmonary cases of TB recorded in
Poland during 2004.
Primary isolation was performed using Lo¨wen-
stein–Jensen medium and the BACTEC 460-TB
system (Becton Dickinson, Franklin Lakes, NJ,
USA), with species identification based on niacin
tests, the use of gene probes (Gen-Probe, San
Diego, CA, USA) and HPLC analysis of mycolic
acids. Drug susceptibility testing used the 1% pro-
portion method in Lo¨wenstein–Jensen medium.
The drugs tested (and their critical concentrations)
were: isoniazid (0.2 mg ⁄L), rifampicin (40 mg ⁄L),
streptomycin (4 mg ⁄L), and ethambutol (2 mg ⁄L)
[3]. Bacterial DNA was prepared by the cetyl-
trimethyl-ammonium bromide method [4]. Spol-
igotyping was performed using a commercially
available kit (Isogen Bioscience BV, Maarssen, The
Netherlands) according to the manufacturer’s
instructions and as described previously [1].
IS6110-Mtb1 ⁄Mtb2 PCR was also performed as
described previously [2]. Isolates with indistin-
guishable spoligotypes and IS6110-Mtb1 ⁄Mtb2
patterns were assumed to be clonally related
and to be linked by recent transmission events.
Drug susceptibility testing revealed that 38
(79%) isolates were resistant to only one drug.
Isoniazid and streptomycin mono-resistance were
represented almost equally, accounting for 33%
and 37% of the total isolates, respectively. Nearly
two-thirds of the isolates resistant to a single drug
were from patients with no history of treatment.
Eight (17%) isolates were multidrug-resistant
(MDR), of which six were from previously treated
patients.
In total, 26 distinct spoligotypes were identified
among the 48 M. tuberculosis isolates tested, with
19 (40%) isolates represented by a unique pattern,
and 29 (60%) isolates grouped in seven clusters,
each containing two to eight isolates. Of the 19
unique profiles, 13 (27%) belonged to a previ-
ously described ‘shared type’ (ST) according to
the worldwide spoligotype database (SpolDB4),
while six did not match any existing spoligotype
and were thus defined as ‘orphans’. Among the
seven clusters recognised, one was not found
in SpolDB4. The most frequent spoligotypes
observed were ST53 and ST47, both representing
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15 (31%) of the isolates studied. Also, two isolates
of the Beijing genotype (ST1) were identified.
IS6110-Mtb1 ⁄Mtb2 PCR typing revealed that 17
(35%) isolates included in spoligotype clusters
produced unique banding patterns. Only two
spoligotype clusters, comprising two and four
isolates, respectively, contained isolates that were
identical according to IS6110-Mtb1 ⁄Mtb2 PCR.
The 19 isolates with unique spoligotypes also
generated unique IS6110-Mtb1 ⁄Mtb2 PCR
patterns. Clustering results obtained according
to both genotyping methods are summarised in
Table 1. Overall, the combination of spoligotyp-
ing and IS6110-Mtb1 ⁄Mtb2 PCR assigned 12
(25%) of the 48 isolates to four different clusters,
containing isolates from four, three, three and two
patients, respectively (Table 2).
The two most prevalent spoligotypes (ST53 and
ST47) were responsible for almost one-third of the
TB cases studied. These spoligotypes, along with
ST50 and ST1051, were also the top-ranked
genotypes among drug-resistant M. tuberculosis
isolates in Poland during 2000 [5], and, except for
ST1051, are among the most frequent worldwide
[6]. In addition to the 19 spoligotypes defined
previously, seven new types were identified, of
which six were orphans and one, comprising four
isolates, was a new ST. The presence of these new
and unique spoligotypes, especially the one com-
prising a cluster, suggests that they are specific to
the study setting. Overall, ten (21%) of the cases
were caused by M. tuberculosis isolates whose
spoligotypes had not been described previously.
Two isolates belonging to the Beijing family
(ST1) were identified. This genotype has been
associated frequently with drug resistance and TB
outbreaks worldwide [7,8], and Beijing strains are
very common in Poland’s eastern neighbours,
Estonia and Russia, with prevalences of 29% and
44.5%, respectively [9,10]. Beijing strains have
been described previously in Poland [5], which
suggests a continuing presence of the Beijing
genotype in the region; nevertheless, it was
possible to discriminate between the two Beijing
isolates in this study, which left them outside any
chain of recent transmission.
Although spoligotyping is a convenient and
rapid method for preliminary screening, it over-
estimates the number of epidemiologically linked
cases [11,12]. Consequently, spoligotyping has
been proposed as a first-line test in a two-step
strategy for M. tuberculosis typing, to be followed
by another PCR-based fingerprinting method with
a higher discrimination level [11]. Such a strategy
was intended as an alternative to IS6110 restriction
fragment length polymorphism typing, which is
still regarded as the reference standard for
M. tuberculosis typing [13,14]. In the present study,
spoligotyping was combined with IS6110-
Mtb1 ⁄Mtb2 PCR [2], which has a discriminatory
power close to that of IS6110 restriction fragment
length polymorphism typing [15]. Two previous
studies have also used IS6110-Mtb1 ⁄Mtb2 PCR for
epidemiological studies of TB [15,16]. Overall,
based on identical spoligotyping and IS6110-
Mtb1 ⁄Mtb2 banding patterns, 12 M. tuberculosis
isolates were assigned to four clonally related
groups, suggesting that 25% of the TB cases
studied resulted from recent transmission events.
However, clustering ofM. tuberculosis isolatesdoes
not always represent recent transmission, and can
also reflect the persistence of well-conserved
endemic strains [17]. The absence of epidemiolog-
ical data to confirm a clonal relationship among the
isolates was an important limitation of this study.
Phenotypic characterisation revealed thatmono-
resistance to either isoniazid or streptomycin was
Table 1. Summary of clustering results obtained accord-
ing to the two genotyping methods used in this study
Method
No. of clustered
isolates (%)
No. of
clusters
Size of cluster
(no. of isolates)
Spoligotyping 29 (60) 7 2–8
IS6110-Mtb1 ⁄Mtb2 PCR 12 (25) 4 2–4
Table 2. General characteristics of tuberculosis cases
linked by recent transmission on the basis of clustering
results
Cluster
Patient
no.a
Type of
resistanceb
Drug
resistance
profileSpoligotyping
IS6110-Mtb1 ⁄
Mtb2 PCR
I 53 A 3 P INH
9 P INH
14 P INH
II 1253 B 5 P INH
10 P INH
III Nfc C 18 P SM
25 P SM
29 A SM
31 A SM
IV 47 D 19 P INH
23 P INH
44 A RMP
aCorresponds to the isolate number.
bP, primary; A, acquired.
cSpoligotype not found in the worldwide spoligotype database.
INH, isoniazid; SM, streptomycin; RMP, rifampicin.
606 Clinical Microbiology and Infection, Volume 14 Number 6, June 2008
 2008 National Tuberculosis and Lung Diseases Research Institute, 14, 605–624
most frequent, which is broadly consistent with
other findings worldwide [18]. Disturbingly, eight
of the isolates, including the Beijing isolates, were
MDR. However, in most cases, multidrug resis-
tance status was probably a result of incomplete or
inadequate treatment rather than an ongoing
transmission of MDR strains. Indeed, none of the
MDR isolates formed part of definite clonally
related clusters. Two of the clusters were com-
posed exclusively of isoniazid-resistant isolates;
one contained only streptomycin-resistant isolates
and one contained two isoniazid-resistant iso-
lates and one rifampicin-resistant isolate. These
observations favour a close relationship among
M. tuberculosis isolates belonging to the same
cluster, suggesting transmission of the same
drug-resistant strain among the patients within
the cluster [5].
In conclusion, a combination of two PCR-based
methods, spoligotyping and IS6110-Mtb1 ⁄Mtb2,
was shown to be useful for determining the
relatedness among M. tuberculosis isolates and
defining epidemiological links in central Poland.
Nevertheless, to better determine the utility of this
approach for studying themolecular epidemiology
of TB, a larger pool of isolates from geographically
distinct regions should be analysed.
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